Anavex Life Sciences (AVXL) Net Cash Flow Growth (1y) (2011 - 2025)
Anavex Life Sciences (AVXL) Net Cash Flow Growth (1y) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Anavex Life Sciences | 223.91 Mn | 92.16 Mn | - | 355.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 355.63% |
| Sep 30, 2025 | 121.51% |
| Jun 30, 2025 | -2,218.57% |
| Mar 31, 2025 | -14.27% |
| Dec 31, 2024 | -57.21% |
| Sep 30, 2024 | -73.19% |
| Jun 30, 2024 | -146.67% |
| Mar 31, 2024 | -144.48% |
| Dec 31, 2023 | -31.12% |
| Sep 30, 2023 | 6.15% |
| Jun 30, 2023 | 1,042.71% |
| Mar 31, 2023 | 348.27% |
| Dec 31, 2022 | -475.83% |
| Sep 30, 2022 | 25.87% |
| Jun 30, 2022 | -100.18% |
| Mar 31, 2022 | -92.29% |
| Dec 31, 2021 | -105.31% |
| Sep 30, 2021 | -434.51% |
| Jun 30, 2021 | 7,636.27% |
| Mar 31, 2021 | 3,283.30% |